Eiji Kikuchi

15.1k total citations · 3 hit papers
350 papers, 7.3k citations indexed

About

Eiji Kikuchi is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Eiji Kikuchi has authored 350 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 214 papers in Surgery, 113 papers in Pulmonary and Respiratory Medicine and 78 papers in Oncology. Recurrent topics in Eiji Kikuchi's work include Bladder and Urothelial Cancer Treatments (172 papers), Urinary and Genital Oncology Studies (119 papers) and Prostate Cancer Treatment and Research (51 papers). Eiji Kikuchi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (172 papers), Urinary and Genital Oncology Studies (119 papers) and Prostate Cancer Treatment and Research (51 papers). Eiji Kikuchi collaborates with scholars based in Japan, United States and Germany. Eiji Kikuchi's co-authors include Mototsugu Oya, Akira Miyajima, Takeo Kosaka, Shahrokh F. Shariat, Shuji Mikami, Yair Lotan, Kazuhiro Matsumoto, Ken Nakagawa, Nobuyuki Tanaka and Vitaly Margulis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The EMBO Journal.

In The Last Decade

Eiji Kikuchi

338 papers receiving 7.2k citations

Hit Papers

Outcomes of radical nephroureterectomy: A series from the... 2009 2026 2014 2020 2009 2016 2023 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
    2009 780 citations Vitaly Margulis, Shahrokh F. Shariat et al. profile →
  2. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
    2016 261 citations Shahrokh F. Shariat, Wassim Kassouf et al. profile →
  3. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    2023 84 citations Thomas Powles, Begoña P. Valderrama et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eiji Kikuchi Japan 40 4.5k 2.1k 1.5k 1.3k 1.2k 350 7.3k
Akira Miyajima Japan 37 1.7k 0.4× 1.6k 0.8× 953 0.6× 502 0.4× 1.5k 1.2× 274 5.1k
Syed A. Hussain United Kingdom 37 2.4k 0.5× 964 0.5× 1.4k 0.9× 601 0.5× 1.4k 1.2× 231 5.4k
Robert S. Svatek United States 43 4.6k 1.0× 1.2k 0.6× 1.4k 0.9× 1.5k 1.2× 1.3k 1.1× 211 6.2k
E. David Crawford United States 38 3.5k 0.8× 5.1k 2.5× 1.5k 1.0× 1.6k 1.3× 990 0.8× 133 9.1k
Jie Cai China 35 1.4k 0.3× 696 0.3× 1.2k 0.8× 501 0.4× 813 0.7× 163 3.8k
Gedske Daugaard Denmark 47 4.8k 1.1× 2.2k 1.1× 2.6k 1.7× 137 0.1× 2.0k 1.6× 256 8.9k
Seiichiro Ozono Japan 35 930 0.2× 1.4k 0.7× 493 0.3× 906 0.7× 973 0.8× 207 3.5k
Takeo Kosaka Japan 39 1.5k 0.3× 1.6k 0.8× 1.2k 0.8× 172 0.1× 1.7k 1.4× 290 4.8k
Amlesh Seth India 35 1.1k 0.3× 2.2k 1.1× 489 0.3× 689 0.5× 925 0.8× 231 4.3k
В. Б. Матвеев Russia 22 1.2k 0.3× 6.1k 3.0× 1.5k 1.0× 469 0.4× 1.0k 0.9× 184 7.4k

Countries citing papers authored by Eiji Kikuchi

Since Specialization
Citations

This map shows the geographic impact of Eiji Kikuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiji Kikuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiji Kikuchi more than expected).

Fields of papers citing papers by Eiji Kikuchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiji Kikuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiji Kikuchi. The network helps show where Eiji Kikuchi may publish in the future.

Co-authorship network of co-authors of Eiji Kikuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Eiji Kikuchi. A scholar is included among the top collaborators of Eiji Kikuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiji Kikuchi. Eiji Kikuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kitamura, Hiroshi, et al.. (2025). JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan. Scientific Reports. 15(1). 41773–41773.
2.
Shirai, Masato, Akira Tsujimura, Shinichiro Fukuhara, et al.. (2025). Prevalence and Factors Associated with Premature Ejaculation in Japan: First Nationwide Cross-Sectional Survey by the Japanese Society for Sexual Medicine. The World Journal of Men s Health. 44(2). 334–334. 1 indexed citations
3.
Hayakawa, Nozomi, Eiji Kikuchi, Ryo Yamashita, et al.. (2024). Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study. Japanese Journal of Clinical Oncology. 54(11). 1194–1200. 7 indexed citations
4.
Powles, Thomas, Michiel S. van der Heijden, Shilpa Gupta, et al.. (2024). 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Annals of Oncology. 35. S1137–S1138. 13 indexed citations
5.
Tsujimura, Akira, Shinichiro Fukuhara, Kōji Chiba, et al.. (2024). Erectile Function and Sexual Activity Are Declining in the Younger Generation: Results from a National Survey in Japan. The World Journal of Men s Health. 43(1). 239–239. 7 indexed citations
6.
Kikuchi, Eiji, Michiel S. van der Heijden, Begoña P. Valderrama, et al.. (2024). 269O Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39. Annals of Oncology. 35. S1507–S1508. 1 indexed citations
7.
8.
Kikuchi, Eiji, Hiroyuki Yamamoto, Takahiro Yasui, et al.. (2024). The first detailed annual record on the National Clinical Database Urology Division in Japan: A report on five surgical procedures. International Journal of Urology. 31(12). 1344–1355. 4 indexed citations
9.
10.
Lee, Lui Shiong, Eiji Kikuchi, Hiroshi Kitamura, et al.. (2023). Risk stratification and management of non‐muscle‐invasive bladder cancer: A physician survey in six Asia‐Pacific territories. International Journal of Urology. 31(1). 64–71. 1 indexed citations
11.
Powles, Thomas, Begoña P. Valderrama, Shilpa Gupta, et al.. (2023). LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Annals of Oncology. 34. S1340–S1340. 84 indexed citations breakdown →
12.
13.
Prieto‐Vila, Marta, Wataru Usuba, Yusuke Yoshioka, et al.. (2022). High‐grade bladder cancer cells secrete extracellular vesicles containing miRNA‐146a‐5p and promotes angiogenesis. SHILAP Revista de lepidopterología. 1(8). e47–e47. 3 indexed citations
14.
15.
Miyazaki, Yasumasa, Takeo Kosaka, Shuji Mikami, et al.. (2012). The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma. Clinical Cancer Research. 18(15). 4145–4153. 38 indexed citations
16.
17.
Ide, Hiroki, Jun Nakashima, Eiji Kikuchi, et al.. (2009). Prognostic Stratification in Patients Who Received Hormonal Therapy for Prostate-specific Antigen Recurrence after Radical Prostatectomy. Japanese Journal of Clinical Oncology. 40(2). 177–180. 3 indexed citations
18.
Kikuchi, Eiji, Vitaly Margulis, Pierre I. Karakiewicz, et al.. (2008). Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology. 27(4). 612–618. 215 indexed citations
19.
Nakashima, Jun, Eiji Kikuchi, Akira Miyajima, et al.. (2008). Simple Stratification of Survival Using Bone Scan and Serum C-Reactive Protein in Prostate Cancer Patients with Metastases. Urologia Internationalis. 80(2). 129–133. 22 indexed citations
20.
Liang, Ruilu, et al.. (2002). Zinc Dust Recycling Technique. Magnetic Separation of Fine Particles.. Journal of the Society of Powder Technology Japan. 39(3). 161–168. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akira Miyajima Breakdown of academic impact, for papers by Syed A. Hussain Breakdown of academic impact, for papers by Robert S. Svatek Breakdown of academic impact, for papers by E. David Crawford Breakdown of academic impact, for papers by Jie Cai Breakdown of academic impact, for papers by Gedske Daugaard Breakdown of academic impact, for papers by Seiichiro Ozono Breakdown of academic impact, for papers by Takeo Kosaka Breakdown of academic impact, for papers by Amlesh Seth Breakdown of academic impact, for papers by В. Б. Матвеев
Rankless by CCL
2026